GlassScriptPhysician profile
Christina Rodriguez
NPI 1780285049
$8,942.75
in general payments reported to CMS, 2019-2025
22 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,398 · 2022: $1,701 · 2023: $2,099 · 2024: $3,503 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961 · Consulting Fee: $2,332 · Travel and Lodging: $304 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.29 |
| Consulting Fee | $2,332.00 |
| Travel and Lodging | $303.97 |
| Education | $246.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,889.28 | 2021-2024 | |
| Janssen Biotech, INC. | $1,710.74 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,595.38 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $580.68 | 2021-2024 | |
| Incyte Corporation | $337.07 | 2022-2024 | Opzelura, Jakafi |
| Sun Pharmaceutical Industries INC. | $266.05 | 2021-2024 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $258.96 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $229.74 | 2022-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $187.76 | 2021-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $128.77 | 2021-2024 | Arazlo |
| Organon LLC | $127.49 | 2023-2024 | Hadlima |
| Gilead Sciences, INC. | $113.49 | 2023 | Trodelvy |
| Ucb, INC. | $105.31 | 2022-2024 | Bimzelx, Cimzia |
| Tg Therapeutics, INC. | $101.29 | 2025 | |
| Lilly USA, LLC | $60.74 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.44 | 2022 | |
| Merz North America, INC. | $47.84 | 2021-2024 | |
| Amgen INC. | $34.33 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.32 | 2024 | Hyqvia |
| Galderma Laboratories, L.P. | $31.57 | 2021-2024 | |
| Genentech, INC. | $22.69 | 2023 | Rituxan |
| Phadia US INC. | $18.81 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.